• Actinogen Medical shares rose 8.82% on 1 April 2026 following a clinical trial update.
  • The company commenced the open-label extension phase of its XanaMIA Alzheimer’s trial.
  • All participants in the extension phase will receive active Xanamem treatment
  • The extension phase is designed to generate long-term safety and observational efficacy data
  • Data from the trial is expected to support future regulatory applications

Actinogen Medical Ltd shares (ASX:ACW) climbed 8.82% to AUD 0.037 during the afternoon session on 1 April 2026, with the stock now up 23.33% over the past year. Today’s upward movement followed the company’s announcement that it has initiated the open-label extension phase of its ongoing XanaMIA Alzheimer’s disease trial, marking another step forward in its clinical development program.

Advancement in Alzheimer’s Trial Progress

The company confirmed that the first participant in the open-label extension (OLE) phase has already been treated, signalling the formal commencement of this next stage. This phase allows both current and past participants who have completed the randomized portion of the XanaMIA trial to receive active treatment.

Unlike the earlier randomized stage, the extension phase does not include a placebo group. Instead, all participants will receive a daily 10 mg dose of Xanamem, enabling broader exposure to the investigational therapy. The treatment period in this phase can extend up to 25 months, offering a longer observation window.

Importantly, this stage is structured to collect extended safety data while also monitoring key measures of efficacy. These include cognitive performance, daily functioning, and the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB), a widely recognised benchmark in Alzheimer’s research.

Generating Long-Term Data to Support Future Pathways

The open-label format provides flexibility in how data is analysed and reported. Results can be assessed progressively and compared with historical datasets involving patients with mild to moderate Alzheimer’s disease.

This approach is expected to contribute valuable insights into the longer-term effects of Xanamem, particularly regarding durability of response and safety over extended use. The data generated is also intended to play a role in supporting future regulatory submissions.

At the same time, the randomized phase of the XanaMIA trial continues independently. This component of the study remains ongoing, with final topline results anticipated in November 2026.

Expanding Access to Active Treatment

The commencement of the extension phase enables all eligible participants—including those who previously received placebo—to access the active therapy. This transition allows for broader participation in evaluating the treatment’s effects over time.

According to the company, this phase provides an opportunity to gather meaningful data on how patients respond to continuous exposure to Xanamem. It also supports the collection of longer-term safety observations across a wider participant base.

Focus on a Novel Mechanism in Neurological Treatment

Actinogen Medical Ltd is focused on developing treatments for neurological and neuropsychiatric conditions linked to elevated cortisol levels in the brain. Its lead compound, Xanamem, is designed to regulate cortisol by targeting the enzyme responsible for its production within brain cells.

This mechanism aims to address the harmful effects associated with excess cortisol, which has been linked to cognitive decline and damage to brain cells. The therapy is being explored as a potential option for slowing or altering disease progression in Alzheimer’s disease.

Beyond Alzheimer’s, the company has also investigated Xanamem in other conditions, including depression associated with cognitive impairment, and may explore additional neurological indications in the future.

Ongoing Clinical Development and Trial Scope

The broader XanaMIA trial is a Phase 2b/3 study involving patients with mild to moderate Alzheimer’s disease. Participants in the randomized phase receive either Xanamem or placebo over a 36-week period, with outcomes measured across multiple clinical endpoints.

The study is being conducted across sites in Australia and the United States and has completed recruitment. It has also passed an independent safety and futility review conducted by a Data Monitoring Committee.

Meanwhile, the newly launched open-label extension phase builds on this framework by extending treatment duration and expanding data collection parameters.

What This Means for Investors?

The latest update highlights continued progress in Actinogen Medical’s clinical program, with the initiation of the open-label extension phase representing a meaningful development in the XanaMIA trial pathway. The ability to gather longer-term safety and efficacy data, alongside ongoing randomized trial results expected later in 2026, appears to be contributing to today’s share price strength.

With multiple clinical milestones underway and further data anticipated, investors are closely monitoring how outcomes from both phases of the trial may shape future development and regulatory directions.